SCHEMBL24944156

SCHEMBL24944156

CNc1nc(Nc2ccc(N3CCOCC3)cc2C)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 3/20 0.40
▸ MAPK10 P53779 3/20 0.40
▸ MAPK8 P45983 2/20 0.40
▸ TTK P33981 8/20 0.40
▸ LRRK2 Q5S007 3/20 0.40
▸ ALK Q9UM73 4/20 0.38
▸ EML4 Q9HC35 2/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ INSR P06213 2/20 0.37
▸ AURKA O14965 2/20 0.37
▸ CDK2 P24941 2/20 0.37
▸ CDC7 O00311 1/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ DCLK1 O15075 1/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ DAPK3 O43293 1/20 0.37
▸ DYRK3 O43781 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ PRKD3 O94806 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173575 0.92 LRRK2 (0.42) MAPK9MAPK10MAPK8TTKLRRK2
SCHEMBL30206122 0.92 LRRK2 (0.42) MAPK9MAPK10MAPK8TTKLRRK2
SCHEMBL30205517 0.92 MAPK9 (0.48) MAPK9MAPK10MAPK8LRRK2ALK
SCHEMBL24943795 0.92 MAPK9 (0.44) MAPK9MAPK10MAPK8TTKLRRK2
SCHEMBL24944367 0.92 MAPK9 (0.48) MAPK9MAPK10MAPK8LRRK2ALK
SCHEMBL24944969 0.91 LRRK2 (0.51) MAPK9MAPK10MAPK8TTKLRRK2
SCHEMBL24943791 0.89 EML4 (0.48) ALKEML4AURKACDK2LCK
SCHEMBL24944378 0.87 EML4 (0.46) ALKEML4AURKACDK2LCK
SCHEMBL24943836 0.86 EML4 (0.36) MAPK9MAPK10ALKEML4AURKA
SCHEMBL24944164 0.85 RET (0.36) MAPK9MAPK10MAPK8LRRK2ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback